Completed
Safety Evaluation of Lofexidine for Treatment of Opioid Withdrawal
Led by National Institute on Drug Abuse (NIDA) · Updated on 2017-01-12
N/A
Participants Needed
1
Research Sites
13 weeks
Total Duration
On this page
Sponsors
N
National Institute on Drug Abuse (NIDA)
Lead Sponsor
U
University of Pennsylvania
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to determine the safety of lofexidine in the treatment of opiate withdrawal. Preliminary data will also be obtained to assess the ability of lofexidine to alleviate opiate withdrawal signs and symptoms.
CONDITIONS
Official Title
Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 3
Who Can Participate
Eligibility Criteria
You may qualify if you...
Please contact site for information.
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
Trial Site Locations
Total: 1 location
1
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104 6178
Status Unknown
How is the study designed?
Study Type
INTERVENTIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
TREATMENT
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here